Serum Lipid Biomarkers for Diagnosing Alzheimer's Disease ID: 2016-029
This technology identifies novel serum lipid biomarkers for early diagnosis and effective staging of Alzheimer's disease.
Photo by filin174 - stock.adobe.com
Technology Overview
The invention involves the discovery of specific biomolecules in human serum that can diagnose Alzheimer's disease at its earliest stages and assist in disease staging. These biomarkers are unique, offering a new approach to Alzheimer's diagnostics that differs significantly from existing methods.
Key Advantages
- Enables early detection of Alzheimer's disease, potentially before clinical symptoms appear
- Assists in the accurate staging of the disease, facilitating better patient management
- Offers a non-invasive diagnostic tool through simple blood tests
- Novel biomarkers that provide a new direction for Alzheimer's research and diagnostics
Problems Addressed
- Difficulty in diagnosing Alzheimer's disease at an early stage
- Challenges in accurately staging the disease based on clinical observations alone
- Lack of non-invasive, cost-effective diagnostic methods
Market Applications
- Diagnostic laboratories and clinics specializing in neurodegenerative diseases
- Pharmaceutical companies focusing on Alzheimer's disease treatment and management
- Academic and research institutions for further research on Alzheimer's disease biomarkers
- Development of personalized medicine approaches for Alzheimer's disease patients
Additional Information
Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report